AAM All Access Podcast - Dan Leonard speaks with Mary Beth Powers, President and CEO of CMMB.

Complex Generics & the Prescription Drug Landscape

February 9, 2021

1:00 PM ET / 10:00 AM PT

Many American adults—nearly 60 million, according to some recent consumer surveys—have difficulty affording their prescription drug medicines even with insurance, putting their health and financial priorities at odds.

Complex generics have the potential to generate significant savings for patients and the health care system. But market dynamics and regulatory complexities are seen as significant hurdles.

Watch Recording

What policies can be put into place to safely accelerate evaluation and approval timelines? How could next year’s reauthorization of the Generic Drug User Fee Amendments create opportunities to institute innovative policy changes and how is the pandemic’s spotlight on therapeutics and pharmaceutical development timelines likely to influence the thinking behind complex generic approval processes?

Join The Hill for a discussion with leading medical voices, policy experts and members of Congress to discuss how complex generic medical alternatives can impact and enhance the American health care system.

Sponsored by the Association for Accessible Medicines.


  • Tammy Boyd, Chief Policy Officer & Counsel, Black Women’s Health Imperative
  • Alex Brill, Founder and CEO, Matrix Global Advisors; Resident Fellow, American Enterprise Institute
  • Dr. Sally Choe, Director, Office of Generic Drugs, FDA
  • Dr. Kashyap Patel, CEO, Carolina Blood and Cancer Care
  • Rep. Peter Welch (D-VT), Co-Chair and Founder, Congressional Affordable Medicines Caucus
  • Tonya Winders, President and CEO, Allergy & Asthma Network

Additional speakers to be announced.


  • Steve Clemons, Editor-at-Large, The Hill

Join the conversation! On Twitter, use @accessiblemeds@TheHillEvents and #TheHillRx

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.